The neurodegenerative diseases, Alzheimer's disease (AD) and Parkinson's disease (PD), are age-related disorders characterized by the deposition of abnormal forms of specific proteins in the brain. AD is characterized by the presence of extracellular amyloid plaques and intraneuronal neurofibrillary tangles in the brain. Biochemical analysis of amyloid plaques revealed that the main constituent is fibrillar aggregates of a 39-42 residue peptide referred to as the amyloid-β protein (Aβ). PD is associated with the degeneration of dopaminergic neurons in the substantia nigra pars compacta. One of the pathological hallmarks of PD is the presence of intracellular inclusions called Lewy bodies that consist of aggregates of the presynaptic soluble protein called α-synuclein. There are various factors influencing the pathological depositions, and in general, the cause of neuronal death in neurological disorders appears to be multifactorial. However, it is clear, that the underlying factor in the neurological disorders is increased oxidative stress substantiated by the findings that the protein side-chains are modified either directly by reactive oxygen species (ROS) or reactive nitrogen species (RNS), or indirectly, by the products of lipid peroxidation. The increased level of oxidative stress in AD brain is reflected by the increased brain content of iron (Fe) and copper (Cu) both capable of stimulating free radical formation (e.g. hydroxyl radicals via Fenton reaction), increased protein and DNA oxidation in the AD brain, enhanced lipid peroxidation, decreased level of cytochrome c oxidase and advanced glycation end products (AGEs), carbonyls, malondialdehyde (MDA), peroxynitrite, and heme oxygenase-1 (HO-1). AGEs, mainly through their interaction with receptors for advanced glycation end products (RAGEs), further activate signaling pathways, inducing formation of proinflammatory cytokines such as interleukin-6 (IL-6). The conjugated aromatic ring of tyrosine residues is a target for free-radical attack, and accumulation of dityrosine and 3-nitrotyrosine has also been reported in AD brain. The oxidative stress linked with PD is supported by both postmortem studies and by studies showing the increased level of oxidative stress in the substantia nigra pars compacta, demonstrating thus the capacity of oxidative stress to induce nigral cell degeneration. Markers of lipid peroxidation include 4-hydroxy-trans-2-nonenal (HNE), 4-oxo-trans-2-nonenal (4-ONE), acrolein, and 4-oxo-trans-2-hexenal, all of which are well recognized neurotoxic agents. In addition, other important factors, involving inflammation, toxic action of nitric oxide (NO·), defects in protein clearance, and mitochondrial dysfunction all contribute to the etiology of PD. It has been suggested that several individual antioxidants or their combinations can be neuroprotective and decrease the risk of AD or slow its progression. The aim of this review is to discuss the role of redox metals Fe and Cu and non-redox metal zinc (Zn) in oxidative stress-related etiology of AD and PD. Attention is focused on the metal-induced formation of free radicals and the protective role of antioxidants [glutathione (GSH), vitamin C (ascorbic acid)], vitamin E (α-Tocopherol), lipoic acid, flavonoids [catechins, epigallocatechin gallate (EGCG)], and curcumin. An alternate hypothesis topic in AD is also discussed.

Metals, oxidative stress and neurodegenerative disorders

Epidemiological studies have clearly shown that whole-grain cereals can protect against obesity, diabetes, CVD and cancers. The specific effects of food structure (increased satiety, reduced transit time and glycaemic response), fibre (improved faecal bulking and satiety, viscosity and SCFA production, and/or reduced glycaemic response) and Mg (better glycaemic homeostasis through increased insulin secretion), together with the antioxidant and anti-carcinogenic properties of numerous bioactive compounds, especially those in the bran and germ (minerals, trace elements, vitamins, carotenoids, polyphenols and alkylresorcinols), are today well-recognised mechanisms in this protection. Recent findings, the exhaustive listing of bioactive compounds found in whole-grain wheat, their content in whole-grain, bran and germ fractions and their estimated bioavailability, have led to new hypotheses. The involvement of polyphenols in cell signalling and gene regulation, and of sulfur compounds, lignin and phytic acid should be considered in antioxidant protection. Whole-grain wheat is also a rich source of methyl donors and lipotropes (methionine, betaine, choline, inositol and folates) that may be involved in cardiovascular and/or hepatic protection, lipid metabolism and DNA methylation. Potential protective effects of bound phenolic acids within the colon, of the B-complex vitamins on the nervous system and mental health, of oligosaccharides as prebiotics, of compounds associated with skeleton health, and of other compounds such as alpha-linolenic acid, policosanol, melatonin, phytosterols and para-aminobenzoic acid also deserve to be studied in more depth. Finally, benefits of nutrigenomics to study complex physiological effects of the 'whole-grain package', and the most promising ways for improving the nutritional quality of cereal products are discussed.

/pdf/new-hypotheses-for-the-health-protective-mechanisms-of-whole-1j7sw6pesk.pdf

New hypotheses for the health-protective mechanisms of whole-grain cereals: what is beyond fibre?

Therapeutics of Alzheimer's disease: Past, present and future.

/pdf/bioinorganic-chemistry-of-alzheimer-s-disease-1c2f7aq8qe.pdf

Bioinorganic Chemistry of Alzheimer’s Disease

Alzheimer's disease [AD] is the most common cause of dementia in North America. Despite 30+ years of intense investigation, the field lacks consensus regarding the etiology and pathogenesis of sporadic AD, and therefore we still do not know the best strategies for treating and preventing this debilitating and costly disease. However, growing evidence supports the concept that AD is fundamentally a metabolic disease with substantial and progressive derangements in brain glucose utilization and responsiveness to insulin and insulin-like growth factor [IGF] stimulation. Moreover, AD is now recognized to be heterogeneous in nature, and not solely the end-product of aberrantly processed, misfolded, and aggregated oligomeric amyloid-beta peptides and hyperphosphorylated tau. Other factors, including impairments in energy metabolism, increased oxidative stress, inflammation, insulin and IGF resistance, and insulin/IGF deficiency in the brain should be incorporated into all equations used to develop diagnostic and therapeutic approaches to AD. Herein, the contributions of impaired insulin and IGF signaling to AD-associated neuronal loss, synaptic disconnection, tau hyperphosphorylation, amyloid-beta accumulation, and impaired energy metabolism are reviewed. In addition, we discuss current therapeutic strategies and suggest additional approaches based on the hypothesis that AD is principally a metabolic disease similar to diabetes mellitus. Ultimately, our ability to effectively detect, monitor, treat, and prevent AD will require more efficient, accurate and integrative diagnostic tools that utilize clinical, neuroimaging, biochemical, and molecular biomarker data. Finally, it is imperative that future therapeutic strategies for AD abandon the concept of uni-modal therapy in favor of multi-modal treatments that target distinct impairments at different levels within the brain insulin/IGF signaling cascades.

/pdf/brain-insulin-resistance-and-deficiency-as-therapeutic-3akf7f7nge.pdf

Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer's Disease

Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease.

Alzheimer’s disease (AD) is a progressive neurodegenerative brain disorder that gradually destroys a patient’s memory and ability to learn, make judgments, communicate within the social environment, and carry out daily activities. In the course of the disease, short-term memory is affected first, caused by neuronal dysfunction and degeneration in the hippocampus and amygdala. As the disease progresses further, neurons also degenerate and die in other cortical regions of the brain. At this stage, sufferers often experience dramatic changes in personality and behavior, such as anxiety, suspiciousness and agitation, as well as delusions and hallucinations. AD prevalence rates are 1% for individuals between 65 and 69 years old, 3% for those between 70 and 74 years old, 6% for those between 75 and 79 years old, 12% for those between 80 and 84 years old, and 25% for those aged 85 years and older. AD is further characterized by two major neuropathological hallmarks: The deposition of neuritic, β-amyloid (Aβ) peptide-containing senile plaques in hippocampal and cerebral cortical regions of AD patients is accompanied by the presence of intracellular neurofibrillary tangles that occupy much of the cytoplasm of pyramidal neurons. Inflammation, as evidenced by the activation of microglia and astroglia, is another hallmark of AD. Inflammation, including superoxide production (“oxidative burst”), is an important source of oxidative stress in AD patients. The inflammatory process occurs mainly around the amyloid plaques and is characterized by proinflammatory substances released from activated microglia and astroglia. Glia-produced cytokines, including interleukin-1β (IL-1β), IL-6, macrophage colony-stimulating factor, and tumor necrosis factor-α (TNF-α), are prominent molecules in the inflammatory process. Besides morphological alterations, AD is also associated with a markedly impaired cerebral glucose metabolism, as detected by reduced cortical F-labeled desoxyglucose utilization in positron emission tomography of AD patients..

David A Carlson

Papers

Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease.

Lipoic acid as a novel treatment for mild cognitive impairment and early-stage Alzheimer’s disease